Schenkein David P
SEC insider (Form 3/4/5 filer). CIK 0001578200. Director at Prime Medicine, Inc. (PRME) and 2 other issuers. 13 reported Form 4/5 transactions since Sep 2024; latest on Jun 5, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Schenkein David P has filed insider reports for
- Prime Medicine, Inc. (PRME): Director
- Denali Therapeutics Inc. (DNLI): Director
- REGENERON PHARMACEUTICALS, INC. (REGN): Director
Schenkein David P
CIK: 0001578200
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Jun 5, 2026PRME
Prime Medicine, Inc.
AwardDirectStock Option (right to buy)
75K shares- - Jun 3, 2026DNLI
Denali Therapeutics Inc.
AwardDirect6.4K shares- - Jan 2, 2026REGN
REGENERON PHARMACEUTICALS, INC.
AwardDirect155 shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
AwardDirectStock Option (right to buy)
39.1K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
AwardDirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
DispositionDirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
DispositionDirectStock Option (right to buy)
39.1K shares- - Jun 4, 2025PRME
Prime Medicine, Inc.
AwardDirectStock Option (right to buy)
55K shares- - Jun 3, 2025DNLI
Denali Therapeutics Inc.
AwardDirect6K shares- - Jan 2, 2025REGN
REGENERON PHARMACEUTICALS, INC.
AwardDirect166 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  PRME Prime Medicine, Inc. | Award Stock Option (right to buy) | 75,000 | - | - | Direct |
| Jun 3, 2026 |  DNLI Denali Therapeutics Inc. | Award | 6,408 | - | $0 | Direct |
| Jan 2, 2026 |  REGN REGENERON PHARMACEUTICALS, INC. | Award | 155 | - | $0 | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award Stock Option (right to buy) | 39,062 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition Stock Option (right to buy) | 39,062 | - | - | Direct |
| Jun 4, 2025 | PRME Prime Medicine, Inc. | Award Stock Option (right to buy) | 55,000 | - | - | Direct |
| Jun 3, 2025 | DNLI Denali Therapeutics Inc. | Award | 6,037 | - | - | Direct |
| Jan 2, 2025 | REGN REGENERON PHARMACEUTICALS, INC. | Award | 166 | - | $0 | Direct |
1-10 of 13 transactions